NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 12th August 2009 Summary Recently, a number of generic versions of clopidogrel (as either the hydrochloride or besilate salt) have been introduced to the UK market. The existing branded […]
Category Archives: Cardiovascular disease
NPC Archive Item: Early revascularisation offers little over intensive medical therapy in type 2 diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st July 2009 This large trial found no benefit in rates of survival or major vascular events from early versus later revascularisation in people with type 2 diabetes and […]
NPC Archive Item: Independent validation of QRISK supports its superiority over Framingham in the UK population
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st July 2009 This independent validation of the QRISK tool found that QRISK showed better calibration and better discrimination in predicting CV risk than the Framingham-based tool currently recommended […]
NPC Archive Item: July Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 7th July 2009 The MHRA and CHM have published the July edition of Drug Safety Update. This issue gives […]
NPC Archive Item: Clinical trials may underestimate the incidence of statin-related myopathy
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3rd July 2009 A narrative review estimates that the incidence of statin-related myopathy in practice is higher than might be expected from data reported in clinical trials. Although a […]
NPC Archive Item: Ezetimibe and cancer — more reassuring data
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 1st July 2009 An analysis of post-marketing adverse event reports did not find any increased risk of cancer with ezetimibe▼ compared with statins, either alone or when taken in […]
NPC Archive Item: More data question the value of aspirin in primary prevention of CV disease
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15th June 2009 This ATT meta-analywsis found that in the primary prevention of cardiovascular (CV) disease, the balance of benefits and risks with aspirin is unclear. While there appears […]
NPC Archive Item: June Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 11th June 2009 The MHRA and CHM have published the June edition of Drug Safety Update. This issue gives […]
NPC Archive Item: Standard dose statins reduce the risk of CHD in patients with familial hypercholesterolaemia
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 10th June 2009 This retrospective cohort study found that statins significantly reduced the risk of coronary heart disease (CHD) in patients with familial hypercholesterolaemia (FH), even though they were […]
NPC Archive Item: EMEA statement on possible interaction between clopidogrel and proton pump inhibitors
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th June 2009 Concomitant use of proton pump inhibitors (PPIs) and clopidogrel is not advisable unless absolutely necessary, the EU Committee for Medicinal products for Human Use (CHMP) and […]